Glaxosmithkline Plc Adr Stock Current Ratio

GSK Stock

USD 39.27 0.33 0.83%

GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.

		Last Reported	Projected for Next Year
	Current Ratio	0.88	1.51

Current Ratio is expected to rise to 1.51 this year.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GlaxoSmithKline PLC ADR Company Current Ratio Analysis

GlaxoSmithKline PLC's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current GlaxoSmithKline PLC Current Ratio

1.43 X

Most of GlaxoSmithKline PLC's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

GlaxoSmithKline Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Current Ratio. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.5	0.9	0.77	-0.07	0.97	0.91	0.7	0.71	0.7	0.12	0.94	0.5	0.95	-0.16	0.23	0.56	0.19	-0.26	0.57	-0.59	0.59	0.4	0.49	0.5	0.2
Total Stockholder Equity	0.5		0.43	0.1	0.39	0.31	0.48	0.33	0.25	0.33	0.88	0.51	0.38	0.68	-0.23	0.1	0.69	0.13	0.06	0.75	-0.27	0.78	0.7	0.42	0.82	-0.44
Net Debt	0.9	0.43		0.7	-0.09	0.89	0.82	0.65	0.9	0.65	0.08	0.82	0.64	0.84	0.02	0.2	0.5	0.11	-0.05	0.47	-0.49	0.65	0.32	0.58	0.5	0.24
Accounts Payable	0.77	0.1	0.7		-0.1	0.82	0.67	0.53	0.59	0.53	-0.23	0.74	0.35	0.69	-0.06	0.31	0.39	0.09	-0.15	0.39	-0.51	0.27	0.08	0.13	0.24	0.37
Short Term Investments	-0.07	0.39	-0.09	-0.1		-0.09	0.13	0.0	-0.09	0.0	0.42	-0.18	-0.24	0.03	-0.51	0.18	0.39	0.27	0.21	0.54	-0.27	0.11	0.67	-0.19	0.61	-0.51
Total Liab	0.97	0.31	0.89	0.82	-0.09		0.91	0.74	0.75	0.74	-0.11	0.88	0.47	0.86	-0.15	0.23	0.45	0.2	-0.27	0.48	-0.63	0.46	0.33	0.42	0.4	0.25
Total Current Assets	0.91	0.48	0.82	0.67	0.13	0.91		0.88	0.65	0.88	0.06	0.72	0.6	0.79	-0.04	-0.04	0.4	0.15	-0.2	0.48	-0.54	0.41	0.41	0.31	0.47	0.13
Capital Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88		0.55	1.0	-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Short Term Debt	0.71	0.25	0.9	0.59	-0.09	0.75	0.65	0.55		0.55	-0.03	0.65	0.56	0.66	0.12	0.25	0.42	-0.1	0.14	0.34	-0.31	0.55	0.19	0.53	0.37	0.21
Common Stock	0.7	0.33	0.65	0.53	0.0	0.74	0.88	1.0	0.55		-0.14	0.49	0.74	0.55	0.23	-0.33	0.1	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Retained Earnings	0.12	0.88	0.08	-0.23	0.42	-0.11	0.06	-0.14	-0.03	-0.14		0.2	0.03	0.37	-0.29	0.18	0.63	0.03	0.2	0.6	0.02	0.66	0.6	0.32	0.7	-0.44
Intangible Assets	0.94	0.51	0.82	0.74	-0.18	0.88	0.72	0.49	0.65	0.49	0.2		0.38	0.96	-0.26	0.4	0.61	0.22	-0.31	0.61	-0.57	0.7	0.35	0.57	0.51	0.14
Long Term Debt	0.5	0.38	0.64	0.35	-0.24	0.47	0.6	0.74	0.56	0.74	0.03	0.38		0.44	0.65	-0.46	0.02	-0.19	0.1	0.03	-0.06	0.29	-0.08	0.25	0.12	0.13
Good Will	0.95	0.68	0.84	0.69	0.03	0.86	0.79	0.55	0.66	0.55	0.37	0.96	0.44		-0.26	0.36	0.73	0.21	-0.17	0.73	-0.58	0.76	0.52	0.56	0.67	0.03
Property Plant Equipment	-0.16	-0.23	0.02	-0.06	-0.51	-0.15	-0.04	0.23	0.12	0.23	-0.29	-0.26	0.65	-0.26		-0.65	-0.46	-0.59	0.35	-0.64	0.54	-0.34	-0.65	-0.17	-0.56	0.39
Current Deferred Revenue	0.23	0.1	0.2	0.31	0.18	0.23	-0.04	-0.33	0.25	-0.33	0.18	0.4	-0.46	0.36	-0.65		0.7	0.16	0.21	0.57	-0.42	0.46	0.45	0.35	0.49	-0.12
Net Receivables	0.56	0.69	0.5	0.39	0.39	0.45	0.4	0.1	0.42	0.1	0.63	0.61	0.02	0.73	-0.46	0.7		0.02	0.33	0.85	-0.41	0.72	0.77	0.4	0.81	-0.23
Treasury Stock	0.19	0.13	0.11	0.09	0.27	0.2	0.15	0.03	-0.1	0.03	0.03	0.22	-0.19	0.21	-0.59	0.16	0.02		-0.5	0.37	-0.78	0.22	0.34	0.1	0.33	-0.23
Net Tangible Assets	-0.26	0.06	-0.05	-0.15	0.21	-0.27	-0.2	-0.16	0.14	-0.16	0.2	-0.31	0.1	-0.17	0.35	0.21	0.33	-0.5		0.04	0.24	0.01	0.15	-0.04	0.12	-0.13
Long Term Investments	0.57	0.75	0.47	0.39	0.54	0.48	0.48	0.25	0.34	0.25	0.6	0.61	0.03	0.73	-0.64	0.57	0.85	0.37	0.04		-0.65	0.76	0.88	0.45	0.92	-0.52
Short Long Term Debt	-0.59	-0.27	-0.49	-0.51	-0.27	-0.63	-0.54	-0.4	-0.31	-0.4	0.02	-0.57	-0.06	-0.58	0.54	-0.42	-0.41	-0.78	0.24	-0.65		-0.4	-0.56	-0.25	-0.53	0.24
Long Term Debt Total	0.59	0.78	0.65	0.27	0.11	0.46	0.41	0.18	0.55	0.18	0.66	0.7	0.29	0.76	-0.34	0.46	0.72	0.22	0.01	0.76	-0.4		0.6	0.81	0.83	-0.29
Capital Surpluse	0.4	0.7	0.32	0.08	0.67	0.33	0.41	0.21	0.19	0.21	0.6	0.35	-0.08	0.52	-0.65	0.45	0.77	0.34	0.15	0.88	-0.56	0.6		0.36	0.87	-0.59
Net Invested Capital	0.49	0.42	0.58	0.13	-0.19	0.42	0.31	0.14	0.53	0.14	0.32	0.57	0.25	0.56	-0.17	0.35	0.4	0.1	-0.04	0.45	-0.25	0.81	0.36		0.52	-0.1
Net Working Capital	0.5	0.82	0.5	0.24	0.61	0.4	0.47	0.21	0.37	0.21	0.7	0.51	0.12	0.67	-0.56	0.49	0.81	0.33	0.12	0.92	-0.53	0.83	0.87	0.52		-0.47
Cash And Equivalents	0.2	-0.44	0.24	0.37	-0.51	0.25	0.13	-0.02	0.21	-0.02	-0.44	0.14	0.13	0.03	0.39	-0.12	-0.23	-0.23	-0.13	-0.52	0.24	-0.29	-0.59	-0.1	-0.47

Click cells to compare fundamentals

GlaxoSmithKline Current Ratio Historical Pattern

Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GlaxoSmithKline PLC current ratio as a starting point in their analysis.

GlaxoSmithKline PLC Current Ratio

Timeline

Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

Competition

Predict GlaxoSmithKline PLC

Current Ratio Over Time

GlaxoSmithKline Discontinued Operations

Discontinued Operations

12.67 Billion

At this time, GlaxoSmithKline PLC's Discontinued Operations is quite stable compared to the past year.

In accordance with the recently published financial statements, GlaxoSmithKline PLC ADR has a Current Ratio of 1.43 times. This is 50.86% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current ratio for all United States stocks is 33.8% higher than that of the company.

GlaxoSmithKline Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.

GlaxoSmithKline PLC is currently under evaluation in current ratio category among related companies.

GlaxoSmithKline PLC Current Valuation Drivers

We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	140.2B	107.2B	104.6B	117.3B	118.1B	124.0B
Enterprise Value	166.0B	128.0B	124.5B	134.6B	133.2B	139.8B

GlaxoSmithKline Fundamentals

	Return On Equity	0.46
	Return On Asset	0.0881
	Profit Margin	0.16 %
	Operating Margin	0.20 %
	Current Valuation	172.41 B
	Shares Outstanding	2.04 B
	Shares Owned By Institutions	14.42 %
	Number Of Shares Shorted	4.83 M
	Price To Earning	11.80 X
	Price To Book	4.96 X
	Price To Sales	2.75 X
	Revenue	30.33 B
	Gross Profit	19.92 B
	EBITDA	9.29 B
	Net Income	4.93 B
	Cash And Equivalents	3.72 B
	Cash Per Share	0.32 X
	Total Debt	18.02 B
	Debt To Equity	0.98 %
	Current Ratio	1.43 X
	Book Value Per Share	3.29 X
	Cash Flow From Operations	6.35 B
	Short Ratio	1.83 X
	Earnings Per Share	2.99 X
	Price To Earnings To Growth	1.09 X
	Target Price	45.32
	Number Of Employees	70.21 K
	Beta	0.27
	Market Capitalization	81.18 B
	Total Asset	59.01 B
	Retained Earnings	7.24 B
	Working Capital	(2.42 B)
	Current Asset	16.59 B
	Current Liabilities	13.42 B
	Annual Yield	0.04 %
	Five Year Return	5.32 %
	Net Asset	59.01 B
	Last Dividend Paid	0.58

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.

	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Equity Valuation Check real value of public entities based on technical and fundamental data
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Dividend Share

0.58

Earnings Share

2.99

Revenue Per Share

14.97

Quarterly Revenue Growth

0.092

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Glaxosmithkline Plc Adr Stock Current Ratio

GlaxoSmithKline PLC ADR Company Current Ratio Analysis

Current Ratio

Current Asset

Current Liabilities

Current GlaxoSmithKline PLC Current Ratio

GlaxoSmithKline Current Ratio Driver Correlations

GlaxoSmithKline Current Ratio Historical Pattern

GlaxoSmithKline Discontinued Operations

Discontinued Operations

12.67 Billion

GlaxoSmithKline Current Ratio Peer Comparison

GlaxoSmithKline PLC Current Valuation Drivers

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for GlaxoSmithKline Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY